Advinus Therapeutics CEO Rashmi Barbhaiya On Disruptive Innovation And India's R&D Edge: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
Advinus Therapeutics CEO Rashmi Barbhaiya is one of the most visible figures in today's pharmaceutical research in India. Beyond a deep knowledge of life sciences, he is famous for the daring - if not risky - moves that he made nine years ago, when he shifted from Bristol-Myers Squibb to head Ranbaxy's R&D team, and then spearheaded the research ambitions of India's biggest corporate conglomerate - The Tata group.
You may also be interested in...
DNDi Mulls Expansion Of India Site; Set To Team With More Pharma On The Heels Of Sanofi Deal - BIO Conference
WASHINGTON - Six years after establishing its India office, Geneva-based Drugs for Neglected Diseases Initiative (DNDi) is planning to expand its presence to cater to the drug development needs of the Indian population as well as neighboring countries like Bangladesh and Sri Lanka
DNDi Mulls Expansion Of India Site; Set To Team With More Pharma On The Heels Of Sanofi Deal - BIO Conference
WASHINGTON - Six years after establishing its India office, Geneva-based Drugs for Neglected Diseases Initiative (DNDi) is planning to expand its presence to cater to the drug development needs of the Indian population as well as neighboring countries like Bangladesh and Sri Lanka
Advinus Therapeutics CEO Rashmi Barbhaiya On Disruptive Innovation And India's R&D Edge: An Interview With PharmAsia News (Part 1 of 2)
Advinus Therapeutics CEO Rashmi Barbhaiya is one of the most visible figures in today's pharmaceutical research in India. Beyond a deep knowledge of life sciences, he is famous for the daring - if not risky - moves that he made nine years ago, when he shifted from his top job in U.S.-based Bristol-Myers Squibb to head Ranbaxy's R&D team, and then spearheaded the research ambitions of India's biggest corporate conglomerate - The Tata group.